SNFGE SNFGE
 
Thématique :
- Cancers autres (hors CCR et CHC)
Originalité :
Très original
Solidité :
A confirmer
Doit faire évoluer notre pratique :
Immédiatement
 
 
Nom du veilleur :
Professeur Sylvain MANFREDI
Coup de coeur :
 
 
British journal of Cancer
  2018/02  
 
  2018 Feb;118(3):325-330.  
  doi: 10.1038/bjc.2017.413  
 
  Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.  
 
  Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, Matysiak-Budnik T, Bennouna J, Tiako Meyo M, Lecomte T, Zaanan A, Touchefeu Y  
  https://www.ncbi.nlm.nih.gov/pubmed/29169182  
 
 

Abstract

BACKGROUND:

Hepatocholangiocarcinoma (cHCC-ICC) is a rare liver tumour for which no data on chemosensitivity exist. The aims of this multicentre study were to evaluate overall survival (OS), progression-free survival (PFS), and prognostic factors in cHCC-ICC treated by gemcitabine plus platinum as first-line.

METHODS:

Unresectable cHCC-ICC treated by gemcitabine plus platinum-based chemotherapy between 2008 and 2017 were retrospectively analysed. Diagnosis was based on histology or, in case of ICC or HCC histology, on discordant computerised tomography scan enhancement patterns associated with discordant serum tumour marker elevation suggesting the alternative tumour. OS and PFS were evaluated by Kaplan-Meier method and prognostic factors by Log-rank test and Cox model.

RESULTS:

Among 30 patients included, cHCC-ICC was histologically proven in 22 (73.3%). 18 (60%) received gemcitabine plus oxaliplatin (GEMOX), 9 (30%) GEMOX plus bevacizumab, and 3 (10%) gemcitabine plus cisplatin. RECIST criteria were reported in 28 patients: 8 (28.6%) showed partial response, 14 (50%) stable disease, and 6 (21.4%) tumour progression at first evaluation. Median PFS and OS were 9.0 and 16.2 months, respectively. Serum bilirubin ⩾30 μmol l-1 (P=0.001) and positive serology for HBV and/or HCV (P=0.014) were independent poor prognostic factors for OS.

CONCLUSIONS:

Gemcitabine plus platinum-based chemotherapy is effective as first-line for advanced cHCC-ICC.

 

 
Question posée
 
L’association gemcitabine sel de platine est-elle efficace dans le traitement des hépato-cholangiocarcinomes ?
 
Question posée
 
Ce traitement semble efficace.
 
Commentaires

Série rétrospective, non randomisée, seul moyen pour étudier ce cancer très rare.

 
www.snfge.org